ArticleBioinformation2026
A prospective cross-sectional study on pharmacovigilance of antipsychotic drugs at a tertiary care teaching hospital.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotic medications are associated with many adverse drug reactions (ADRs) which affect patient compliance, safety and outcomes, making pharmacovigilance important, that by pharmacovigilance is performed to gather data, make decisions and prevent ADRs of antipsychotic medications. Hence, this is a prospective cross-sectional observational study WHO-UMC scale and Naranjo scale was used to assess the causality of the adverse drug reactions with oral antipsychotic medications. Total 61 patients with adverse drug reactions were observed, 168 adverse drug reactions were observed because of 5 medications; according to WHO-UMC scale 52.45% adverse drug reactions were probable/ likely and according to Naranjo scale 52.45% adverse drug reactions were possible. Pharmacovigilance helps us assess adverse drug reactions, it guides our clinical decision making and drug selection, it gives us data which helps us better perform risk-benefit analysis of drug administration ultimately serving patient wellbeing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.